Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
108.51
(
1.81%
)
Bitcoin
71,212.23
(
-0.04%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: 10nisman post# 100108

Thursday, 07/29/2010 1:27:04 PM

Thursday, July 29, 2010 1:27:04 PM

Post# of 257257

MNTA is trading at an extremely cheap valuation even if TEVA obtains Lovenox approval



That's at least arguable. It's not simply the market share and pricing pressure if Teva gets approved too, it's the changed profit split with Novartis that is the driver in that scenario.

Peter
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now